 |
|
|
| |
Sofosbuvir/Velpatasvir Fixed-Dose Combination for the Treatment of HCV in Patients With Decompensated Liver Disease: the Phase 3 ASTRAL-4 Study
|
| |
| |
Reported by Jules Levin
APASL - 25th Conference of the Asian Pacific
association for the Study of the Liver 2016
Tokyo, Japan
M.R. Charlton,1 J.G. O'Leary,2 N.H. Bzowej,3 A.J. Muir,4 K.M. Korenblat,5 J.M. Fenkel,6 K.R. Reddy,7 E. Lawitz,8 T.D. Schiano,9 L.W. Teperman,10 R.J. Fontana,11 E.R. Schiff,12 M.W. Fried,13 B. Doehle,14 D. An,14 J. McNally,14 A. Osinusi,14 M. Natha,14 D.M. Brainard,14 J.G. McHutchison,14 R.S. Brown,15 M.P. Curry16
1Intermountain Medical Center, Murray, UT; 2Baylor Research Institute, Dallas, TX; 3Ochsner Medical Center, New Orleans, LA; 4Duke University, Durham, NC; 5Washington University School of Medicine in Saint Louis, MO; 6Thomas Jefferson University, Philadelphia, PA; 7University of Pennsylvania School of Medicine, Philadelphia, PA; 8Texas Liver Institute, San Antonio, TX; 9Mount Sinai Hospital, New York, NY; 10NYU School of Medicine, New York, NY; 11University of Michigan, Ann Arbor, MI; 12University of Miami, Coral Gables, FL; 13University of North Carolina at Chapel Hill School of Medicine; 14Gilead Sciences, Inc., Foster City, CA; 15Columbia University Medical Center, New York-Presbyterian, New York, NY; 16Beth Israel Deaconess Medical Center, Boston, MA
|
| |
|
|
|
|
|
